By Gwendolyn Wu | Published September 28, 2026
In the rapidly evolving landscape of regenerative medicine, the promise of "resetting" the immune system has moved from the realm of science fiction to the clinical trial setting. For years, the gold standard for this biological reboot has been personalized CAR-T cell therapy—an approach that has achieved near-miraculous results in oncology and, more recently, in severe autoimmune disorders like lupus.
However, a new clinical readout from Adicet Bio is forcing the pharmaceutical industry to reconsider the logistical and safety hurdles of current cell therapies. Adicet’s latest data, centered on its experimental "gamma delta" T-cell therapy, prula-cel, suggests that the future of autoimmune treatment may lie not in bespoke, patient-derived cells, but in "off-the-shelf" donor-derived alternatives.
The Promise and Peril of Immune Resets
The current wave of interest in CAR-T (chimeric antigen receptor T-cell) therapy for autoimmune diseases is rooted in its ability to effectively "wipe the slate clean." By engineering a patient’s own T-cells to identify and destroy CD19-expressing B-cells—the very cells responsible for the self-attacking antibodies that drive lupus—clinicians have observed deep, drug-free remissions.
Yet, the "personalized" nature of these treatments is their Achilles’ heel. Producing autologous CAR-T therapies is a laborious, multi-week process involving the extraction, genetic modification, and re-infusion of a patient’s own immune cells. This creates a significant barrier to scalability and accessibility. Furthermore, the aggressive nature of these therapies has been linked to severe, and in some cases, fatal, adverse events.
The industry suffered a collective reckoning just weeks ago when major players like Novartis and Bristol Myers Squibb paused their respective clinical programs. The decision followed reports of life-threatening complications, including rare immune reactions that led to patient fatalities in some instances. These setbacks have cast a long shadow over the sector, prompting investors and researchers to demand a safer, more "elegant" solution.
Chronology of a Clinical Pivot
Adicet Bio’s journey toward this moment began with a focus on oncology, where the company initially aimed to leverage the unique properties of gamma delta T-cells to treat lymphoma.
- 2022: Adicet’s stock valuation hit an all-time high as early clinical data demonstrated the potency of its gamma delta platform in cancer patients.
- 2023-2024: As the field of "CAR-T for autoimmunity" began to explode, Adicet pivoted its platform toward systemic lupus erythematosus (SLE). The logic was sound: if these cells could kill cancerous B-cells, they could likely eliminate the pathogenic B-cells in autoimmune disease.
- September 2026: The company released initial data from its early-stage trial of prula-cel. The results served as a proof-of-concept for an "allogeneic" (off-the-shelf) approach, showing the therapy could compete with, and potentially outperform, the safety profiles of existing personalized cell therapies.
Supporting Data: The Case for Gamma Delta Cells
The fundamental distinction between prula-cel and the therapies halted by industry leaders lies in the cellular architecture. While the majority of clinical-stage CAR-T therapies utilize "alpha-beta" T-cells, Adicet has staked its future on gamma delta T-cells.
According to Adicet CEO Chen Schor, this is not a cosmetic difference. In an email to BioPharma Dive, Schor explained that gamma delta cells naturally secrete fewer and lower levels of the pro-inflammatory cytokines—the signaling molecules that, when produced in excess, trigger the dreaded "cytokine release syndrome" (CRS) seen in traditional CAR-T trials.
Safety and Efficacy Metrics
The trial data, while early and based on a small cohort, provided several key takeaways:
- Reduced Toxicity: Only about 25% of patients treated with prula-cel experienced mild or moderate CRS. This stands in stark contrast to the severe, high-grade complications that plagued the now-suspended trials from major competitors.
- Infection Profiles: While the therapy is not without risk—over 50% of patients reported infections—the majority were manageable. Approximately 8% of patients experienced Grade 3 or higher infections, a figure the company argues is acceptable given the severity of the diseases being treated.
- Competitive Efficacy: Jefferies analyst Dennis Ding noted that the efficacy data is "competitive with cell therapy and antibody comps." While peer personalized therapies often boast complete response rates around 40%, Adicet’s early metrics suggest that prula-cel may be able to reach similar therapeutic benchmarks without the same prohibitive safety profile.
Official Responses and Strategic Outlook
The market reaction to the news was paradoxically negative, with Adicet shares dipping 22% by mid-morning on the day of the announcement. This reaction reflects a broader skepticism toward biotech stocks in the current high-interest-rate environment, where investors are wary of the long, capital-intensive road to regulatory approval.
Despite the market volatility, the sentiment from industry observers remains cautiously optimistic. "The data is impressive," noted Ding. "It could encourage pharmaceutical companies to start migrating toward more elegant solutions like gamma delta T-cells."
CEO Chen Schor remains focused on the clinical mission. "What excites us the most is the opportunity to potentially redefine the standard of care for lupus patients from a lifetime of chronic immunosuppressants and steroid treatment," Schor stated. The company is now preparing for a critical next step: discussions with regulatory bodies regarding an expanded, pivotal study focusing on a broader subset of patients, specifically those who do not suffer from lupus nephritis.
Implications for the Future of Autoimmunity
The implications of Adicet’s findings extend far beyond lupus. If prula-cel can successfully navigate Phase 2 and Phase 3 trials, it would validate the "allogeneic" model for a wide range of autoimmune conditions, including multiple sclerosis, rheumatoid arthritis, and systemic sclerosis.
1. The Shift to "Off-the-Shelf"
The shift from autologous to allogeneic cell therapy is the "holy grail" of the sector. By using donor cells, manufacturers can produce thousands of doses from a single batch, drastically reducing the cost-per-dose and the time-to-treatment. This moves cell therapy from a boutique hospital procedure to a scalable, pharmaceutical-grade product.
2. Redefining the Standard of Care
For patients with lupus, the current reality is a cycle of toxic steroid treatments and immunosuppressants that leave the body vulnerable to opportunistic infections. A one-time, or even periodic, "reset" via prula-cel could theoretically offer years of drug-free existence.
3. Regulatory Hurdles
The path forward, however, is not without obstacles. Regulators, spooked by recent fatalities in the CAR-T space, will likely impose rigorous safety monitoring on any future trials. Adicet must demonstrate that the safety advantage of gamma delta cells holds up as the trial size increases.
Conclusion
The data provided by Adicet Bio marks a pivotal moment in the evolution of cellular immunotherapy. While the initial market dip underscores the lingering anxieties surrounding the cell therapy sector, the scientific narrative is shifting. By moving away from the cumbersome and high-risk personalized models of the past, companies like Adicet are paving a path toward a more accessible, safer, and potentially curative future for millions living with chronic autoimmune disease. As the company moves toward its pivotal studies, the entire biopharmaceutical industry will be watching to see if the "gamma delta" revolution can truly deliver on its promise.
About the Author
